

# Aurlien Delluc

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7289317/aurelien-delluc-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35  
papers

493  
citations

11  
h-index

22  
g-index

41  
ext. papers

709  
ext. citations

8.5  
avg, IF

3.65  
L-index

#	Paper	IF	Citations
35	Prevention of post-thrombotic syndrome with rosuvastatin: A multicenter randomized controlled pilot trial (SAVER).. <i>Thrombosis Research</i> , <b>2022</b> , 213, 119-124	8.2	0
34	Efficacy and Safety of Primary Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients with Cancer and Central Venous Catheter: A Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2021</b> , 138, 2139-2139	2.2	
33	Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis with Rivaroxaban: A Pilot, Prospective Cohort Study. <i>Blood</i> , <b>2021</b> , 138, 671-671	2.2	
32	Evaluation of the PADIS score stratifying risk for venous thromboembolism recurrence after a first unprovoked pulmonary embolism. Results from the REVERSE study. <i>European Respiratory Journal</i> , <b>2021</b> ,	13.6	
31	Prevention of the post thrombotic syndrome with anticoagulation: a narrative review. <i>Thrombosis and Haemostasis</i> , <b>2021</b> ,	7	2
30	Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial. <i>Chest</i> , <b>2021</b> ,	5.3	9
29	Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , <b>2021</b> , 208, 79-82	8.2	0
28	Efficacy and safety of primary thromboprophylaxis for the prevention of venous thromboembolism in patients with cancer and a central venous catheter: A systematic review and meta-analysis. <i>Thrombosis Research</i> , <b>2021</b> , 208, 58-65	8.2	2
27	Detection of right ventricular dysfunction in acute pulmonary embolism by computed tomography or echocardiography: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 2504-2513	15.4	0
26	Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 2468-2479	15.4	5
25	Challenging anticoagulation cases: A case of incidental subsegmental pulmonary embolism in a patient with cancer. <i>Thrombosis Research</i> , <b>2021</b> , 197, 77-83	8.2	0
24	ISTH definition of pulmonary embolism-related death and classification of the cause of death in venous thromboembolism studies: Validation in an autopsy cohort. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 2514-2521	15.4	1
23	Statins for venous event reduction in patients with venous thromboembolism: A multicenter randomized controlled pilot trial assessing feasibility. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> ,	15.4	1
22	Arterial and venous thrombosis: What's the link? A narrative review. <i>Thrombosis Research</i> , <b>2020</b> , 191, 97-102	8.2	11
21	Thromboprophylaxis in patients with multiple myeloma. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 493-494		
20	Prevalence of confirmed antiphospholipid syndrome in 18-50 years unselected patients with first unprovoked venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 926-930	15.4	16
19	Long-term risk of postthrombotic syndrome after symptomatic distal deep vein thrombosis: The CACTUS-PTS study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 857-864	15.4	12

18	Yield of ultrasonography in patients with or without post-thrombotic syndrome for diagnosis of suspected recurrent ipsilateral deep vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2654-2657	15.4	
17	Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. <i>Haematologica</i> , <b>2020</b> , 105, 1436-1442	6.6	7
16	Safety of using direct oral anticoagulants in the diagnostic workup of outpatients with suspicion of acute venous thromboembolism. <i>Haematologica</i> , <b>2020</b> , 105, e307-e309	6.6	2
15	Incidence of Cancer after a Second Unprovoked Venous Thromboembolic Event. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 490-495	7	2
14	Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1247-1252	15.4	27
13	Incidence of upper-extremity deep vein thrombosis in western France: a community-based study. <i>Haematologica</i> , <b>2019</b> , 104, e29-e31	6.6	10
12	Management of suspected and confirmed recurrent venous thrombosis while on anticoagulant therapy. What next?. <i>Thrombosis Research</i> , <b>2019</b> , 180, 105-109	8.2	6
11	Real-world incidence of cancer following a first unprovoked venous thrombosis: Results from the EPIGETBO study. <i>Thrombosis Research</i> , <b>2018</b> , 164, 79-84	8.2	12
10	Autosomal dominant familial Behçet disease and haploinsufficiency A20: A review of the literature. <i>Autoimmunity Reviews</i> , <b>2018</b> , 17, 809-815	13.6	41
9	Effect of occult cancer screening on mortality in patients with unprovoked venous thromboembolism. <i>Thrombosis Research</i> , <b>2018</b> , 171, 92-96	8.2	12
8	Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. <i>Lancet Oncology</i> , <b>2016</b> , 17, 193-199	21.7	61
7	Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 967-974	7	56
6	External validation of the modified Ottawa score for risk stratification of recurrent cancer-associated thrombosis. <i>European Journal of Internal Medicine</i> , <b>2016</b> , 36, e11-e12	3.9	10
5	Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. <i>Thrombosis Research</i> , <b>2014</b> , 134, 1214-9	8.2	129
4	Body mass index, a major confounder to insulin resistance association with unprovoked venous thromboembolism. Results from the EDITH case-control study. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 110, 593-7	7	7
3	Lipid parameters and venous thromboembolism: clinical evidence, pathophysiology and therapeutic implications. <i>Clinical Lipidology</i> , <b>2012</b> , 7, 455-469		1
2	Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism. <i>Atherosclerosis</i> , <b>2012</b> , 220, 184-8	3.1	20
1	Lipid lowering drugs and the risk of recurrent venous thromboembolism. <i>Thrombosis Research</i> , <b>2012</b> , 130, 859-63	8.2	29

